A phase III trial has shown improved time to progression with the addition of lapatinib in the setting of locally advanced or metastatic HER2-positive breast cancer, and a phase 2 trial showed a partial response rate of 65.9% for brain metastases with the combination of lapatinib and capecitabine [24, 25]. Here, ERBB2 is linked to breast carcinoma.